Overview Performance Dividends Fundamentals Peer Group Correlations Pair Trades Institutions Insider Forecasts Options

Performance of DNLI Denali Therapeutics | -15.2% in 12m

Compare DNLI with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?

Compare Denali Therapeutics with its related Sector/Index XBI

Compare Denali Therapeutics with its related Sector/Index XBI

Performance Duell DNLI vs XBI

TimeFrame DNLI XBI
1 Day 0.04% 0.55%
1 Week 12.3% 4.13%
1 Month 9.55% 10.14%
3 Months 56.2% 21.77%
6 Months 42.9% 15.22%
12 Months -15.2% 20.63%
YTD 12.7% 12.67%
Rel. Perf. 1m -0.10
Rel. Perf. 3m 0.95
Rel. Perf. 6m 2.38
Rel. Perf. 12m 2.38

Is Denali Therapeutics a good stock to buy?

Neither. Based on ValueRay Analyses, Denali Therapeutics is currently (July 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -4.52 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DNLI as of July 2024 is 21.05. This means that DNLI is currently overvalued and has a potential downside of -12.66% (Sold with Premium).

Is DNLI a buy, sell or hold?

  • Strong Buy: 11
  • Buy: 4
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
Denali Therapeutics has received a consensus analysts rating of 4.63. Therefor, it is recommend to buy DNLI.
Values above 0%: DNLI is performing better - Values below 0%: DNLI is underperforming

Compare DNLI with Broad Market Indices

Symbol 1w 1m 6m 12m
US S&P 500 SPY 13.13% 9.75% 30.45% -35.82%
US NASDAQ 100 QQQ 14.88% 13.17% 33.30% -36.73%
US Dow Jones Industrial 30 DIA 11.55% 5.74% 35.40% -31.50%
German DAX 40 DBXD 10.91% 8.11% 34.76% -30.09%
UK FTSE 100 ISFU 11.11% 6.94% 31.31% -30.40%
Shanghai Shenzhen CSI 300 CSI 300 15.30% 9.85% 40.74% 0.36%
Hongkong Hang Seng HSI 13.72% 10.33% 46.86% 4.78%
Japan Nikkei 225 EXX7 13.81% 10.70% 41.32% -26.14%
India NIFTY 50 INDA 11.16% 6.65% 27.35% -42.17%
Brasil Bovespa EWZ 13.23% 8.16% 56.99% -2.83%

DNLI Denali Therapeutics vs. Sectors

Symbol 1w 1m 6m 12m
Communication Services XLC 13.96% 12.18% 34.53% -38.16%
Consumer Discretionary XLY 15.07% 9.94% 36.03% -21.17%
Consumer Staples XLP 11.79% 7.94% 33.17% -21.91%
Energy XLE 12.49% 7.78% 31.67% -24.14%
Financial XLF 10.99% 3.72% 29.68% -40.22%
Health Care XLV 10.89% 6.91% 34.37% -28.83%
Industrial XLI 11.15% 5.76% 30.79% -31.46%
Materials XLB 10.95% 6.46% 31.24% -23.94%
Real Estate XLRE 11.76% 1.68% 35.24% -25.72%
Technology XLK 14.38% 13.95% 35.29% -37.44%
Utilities XLU 10.82% 6.09% 24.68% -24.98%
Aerospace & Defense XAR 8.66% 3.86% 27.78% -34.96%
Biotech XBI 8.17% -0.59% 27.64% -35.86%
Homebuilder XHB 8.01% -6.45% 19.05% -54.57%
Retail XRT 10.21% 6.92% 31.75% -30.72%

DNLI Denali Therapeutics vs. Commodities

Symbol 1w 1m 6m 12m
Oil USO 14.72% 12.90% 38.74% -19.25%
Natural Gas UNG 17.82% 35.77% 75.78% 37.27%
Gold GLD 12.80% 5.76% 24.88% -36.22%
Silver SLV 16.83% 12.70% 20.71% -27.53%
Copper CPER 14.84% 14.88% 35.74% -18.90%

Returns of DNLI vs. Yields & Bonds

Symbol 1w 1m 6m 12m
iShares 20+ Years Bond TLT 12.22% 9.40% 41.72% -11.82%
iShares High Yield Corp. Bond HYG 11.90% 7.66% 38.84% -25.39%
Does Denali Therapeutics outperform its market, is DNLI a Sector Leader?
No, over the last 12 months Denali Therapeutics (DNLI) made -15.23%, while its related Sector, the SPDR S&P Biotech (XBI) made 20.63%.
Over the last 3 months DNLI made 56.19%, while XBI made 21.77%.
Period DNLI XBI S&P 500
1 Month 9.55% 10.14% -0.20%
3 Months 56.19% 21.77% 7.46%
12 Months -15.23% 20.63% 20.59%